Dianthus Therapeutics (DNTH) News Today $24.66 +0.40 (+1.65%) Closing price 04:00 PM EasternExtended Trading$24.64 -0.02 (-0.10%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Vestal Point Capital LP Has $30.84 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTHSeptember 4 at 7:17 AM | marketbeat.comRA Capital Management L.P. Acquires 1,000,333 Shares of Dianthus Therapeutics, Inc. $DNTHSeptember 4 at 7:02 AM | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by AnalystsSeptember 4 at 2:57 AM | marketbeat.comBraidwell LP Sells 831,234 Shares of Dianthus Therapeutics, Inc. $DNTHSeptember 3 at 7:42 AM | marketbeat.comNuveen LLC Invests $1.17 Million in Dianthus Therapeutics, Inc. $DNTHSeptember 3 at 3:38 AM | marketbeat.comDianthus Therapeutics, Inc. $DNTH Shares Sold by Vanguard Group Inc.September 1 at 3:12 AM | marketbeat.comWalleye Capital LLC Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTHAugust 31, 2025 | marketbeat.comWedbush Forecasts Reduced Earnings for Dianthus TherapeuticsAugust 26, 2025 | americanbankingnews.comWedbush Lowers Earnings Estimates for Dianthus TherapeuticsAugust 26, 2025 | marketbeat.comCandriam S.C.A. Makes New Investment in Dianthus Therapeutics, Inc. $DNTHAugust 25, 2025 | marketbeat.comWedbush Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $42.00August 24, 2025 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 6.7% - Here's What HappenedAugust 21, 2025 | marketbeat.comLifesci Capital Has Bearish Estimate for DNTH Q3 EarningsAugust 17, 2025 | marketbeat.comFY2025 EPS Estimates for DNTH Cut by Cantor FitzgeraldAugust 15, 2025 | marketbeat.comHC Wainwright Has Bearish Forecast for DNTH Q3 EarningsAugust 14, 2025 | marketbeat.comWhat is William Blair's Estimate for DNTH Q1 Earnings?August 12, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from AnalystsAugust 10, 2025 | marketbeat.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial ResultsAugust 7, 2025 | globenewswire.comDianthus Therapeutics (DNTH) Expected to Announce Earnings on ThursdayAugust 7, 2025 | marketbeat.comDianthus Therapeutics’ CAPTIVATE Study: A Potential Game-Changer for CIDP TreatmentJuly 28, 2025 | tipranks.comDianthus Therapeutics (NASDAQ:DNTH) Trading 5.9% Higher - Should You Buy?July 16, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from BrokeragesJuly 15, 2025 | marketbeat.comDianthus Therapeutics Inc News (DNTH) - Investing.comJuly 11, 2025 | investing.comDianthus Therapeutics (NASDAQ:DNTH) Shares Down 4.9% - Here's WhyJuly 10, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8.4% - Time to Buy?July 9, 2025 | marketbeat.comWhat is William Blair's Forecast for DNTH FY2025 Earnings?July 4, 2025 | marketbeat.comMoody Aldrich Partners LLC Takes Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)July 4, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Dianthus Therapeutics (DNTH) with Outperform RecommendationJuly 3, 2025 | msn.comDianthus Therapeutics stock rises after William Blair initiates coverageJuly 2, 2025 | in.investing.comDianthus Therapeutics Shares Climb After Analyst Coverage BoostJuly 2, 2025 | msn.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up - Here's WhyJuly 2, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Earns Outperform Rating from Analysts at William BlairJuly 2, 2025 | marketbeat.comDNTH - Dianthus Therapeutics Inc Price vs Fair Value - MorningstarJune 26, 2025 | morningstar.comMDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 6% - What's Next?June 25, 2025 | marketbeat.comDNTH - Dianthus Therapeutics Inc Dividends - MorningstarJune 24, 2025 | morningstar.comMStifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% UpsideJune 23, 2025 | finance.yahoo.comWhat is Lifesci Capital's Estimate for DNTH Q2 Earnings?June 23, 2025 | marketbeat.comStifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% UpsideJune 21, 2025 | insidermonkey.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by BrokeragesJune 20, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6% - Here's What HappenedJune 11, 2025 | marketbeat.comBrokers Offer Predictions for DNTH FY2026 EarningsJune 10, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Millennium Management LLCJune 3, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.2% - What's Next?May 29, 2025 | marketbeat.comDianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of "Buy" from BrokeragesMay 27, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LPMay 26, 2025 | marketbeat.comDianthus Therapeutics appoints new board memberMay 24, 2025 | investing.comNorthern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)May 23, 2025 | marketbeat.comDianthus Therapeutics Appoints Simon Read, Ph.D., to Board of DirectorsMay 22, 2025 | globenewswire.comPoint72 Asset Management L.P. Reduces Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)May 22, 2025 | marketbeat.com Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNTH Media Mentions By Week DNTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNTH News Sentiment▼1.670.70▲Average Medical News Sentiment DNTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNTH Articles This Week▼73▲DNTH Articles Average Week Get the Latest News and Ratings for DNTH and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Dianthus Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Amneal Pharmaceuticals News Xenon Pharmaceuticals News Kymera Therapeutics News Crinetics Pharmaceuticals News Ultragenyx Pharmaceutical News MorphoSys News Bausch Health Cos News NewAmsterdam Pharma News HUTCHMED News Immunovant News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNTH) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
